Form 4: KEQU CEO Sells 1,000 Shares of Common Stock

Kewaunee Scientific Corp's President and CEO, Thomas David Hull III, reported the sale of 1,000 shares of common stock at a weighted average price of $43.09.

Summary

• Thomas David Hull III, President, CEO, and Director of Kewaunee Scientific Corp (KEQU), reported a transaction involving the company's common stock.
• On October 1, 2025, Mr. Hull disposed of 1,000 shares of common stock.
• The shares were sold at a weighted average price of $43.09 per share, with transaction prices ranging from $43.00 to $43.22.
• Following this transaction, Mr. Hull beneficially owns 38,719 shares of Kewaunee Scientific Corp common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the insider sale by a key executive. While the sale was pre-arranged under a 10b5-1 plan, which mitigates some of the immediate negative implications, any disposition by a CEO can be interpreted as a lack of confidence or a belief that the stock is adequately valued.

Negatives

• A key insider, the President and CEO, disposed of 1,000 shares of common stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This insider transaction report is specific to Kewaunee Scientific Corp and does not directly relate to broader industry trends or competitor activities, beyond the general market perception of insider selling.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal regarding the company's near-term prospects or stock valuation, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

While the sale by the CEO is a negative signal, the transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily indicative of new, adverse information. The amount sold (1,000 shares) represents a relatively small portion of the CEO's remaining holdings (38,719 shares). Investors should hold and monitor for further insider activity or fundamental company news rather than making an immediate sell decision based solely on this single transaction.

Keywords

KEQU, Kewaunee Scientific, Insider Trading, Form 4, Stock Sale, CEO, Director, 10b5-1 Plan